Gene therapy play BrainVectis raises EUR 1M

BrainVectis (Fontenay aux Roses, France) raised EUR 1 million ($1.1 million) in a series A round from private investors.

The company is developing a gene therapy that delivers cytochrome P450 family 46 subfamily A polypeptide 1 ( CYP46A1; CH24H) into the brain to restore normal function of the cholesterol pathway. BrainVectis hopes to start clinical testing of its therapy for Huntington's disease in 2019, and for Alzheimer's disease in 2021. ...